Oligomycin, inhibitor of the F0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis

Oncogene. 2002 Nov 21;21(53):8149-57. doi: 10.1038/sj.onc.1206053.

Abstract

The release of cytochrome c from the intermembrane space of mitochondria into the cytosol is one of the critical events in apoptotic cell death. In the present study, it is shown that release of cytochrome c and apoptosis induced by tumor necrosis factor alpha (TNF) in HeLa cells can be inhibited by (i) overexpression of an oncoprotein Bcl-2, (ii) Cyclosporin A, an inhibitor of the mitochondrial permeability transition pore (PTP) or (iii) oligomycin, an inhibitor of H+- ATP-synthase. Staurosporine-induced apoptosis is sensitive to Bcl-2 but insensitive to Cyclosporin A and oligomycin. The effect of oligomycin is not due to changes in mitochondrial membrane potential or to inhibition of ATP synthesis/hydrolysis since (a) uncouplers (CCCP, DNP) which discharge the membrane potential fail to abolish the protective action of oligomycin and (b) aurovertin B (another inhibitor of H+-ATP-synthase, affecting its F1 component) do not affect apoptosis. A role of oligomycin-sensitive F0 component of H+-ATP-synthase in the TNF-induced PTP opening and apoptosis is suggested.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aurovertins / pharmacology
  • Cyclosporine / pharmacology
  • Cytochrome c Group / metabolism*
  • Cytosol / enzymology
  • Deoxyglucose / pharmacology
  • Emetine / pharmacology
  • Enzyme Inhibitors / pharmacology*
  • Genes, bcl-2
  • HeLa Cells / drug effects
  • HeLa Cells / enzymology
  • Humans
  • Ion Channels / drug effects
  • Ion Channels / physiology
  • Membrane Potentials / drug effects
  • Mitochondria / drug effects*
  • Mitochondria / enzymology
  • Mitochondrial Membrane Transport Proteins
  • Mitochondrial Permeability Transition Pore
  • Neoplasm Proteins / antagonists & inhibitors
  • Oligomycins / pharmacology*
  • Proto-Oncogene Proteins c-bcl-2 / physiology
  • Proton-Translocating ATPases / antagonists & inhibitors*
  • Proton-Translocating ATPases / physiology
  • Recombinant Fusion Proteins / physiology
  • Recombinant Proteins / pharmacology
  • Staurosporine / pharmacology
  • Transfection
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / pharmacology
  • Uncoupling Agents / pharmacology

Substances

  • Aurovertins
  • Cytochrome c Group
  • Enzyme Inhibitors
  • Ion Channels
  • Mitochondrial Membrane Transport Proteins
  • Mitochondrial Permeability Transition Pore
  • Neoplasm Proteins
  • Oligomycins
  • Proto-Oncogene Proteins c-bcl-2
  • Recombinant Fusion Proteins
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Uncoupling Agents
  • aurovertin B
  • Cyclosporine
  • Deoxyglucose
  • Proton-Translocating ATPases
  • Staurosporine
  • Emetine